CTOs on the Move

WaferNet

www.wafernet.com

 
WaferNet is a San Jose, CA-based company in the Computers and Electronics sector.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

Woodpile, The

Woodpile, The is a Dothan, AL-based company in the Computers and Electronics sector.

Oncore Manufacturing Services

OnCore Manufacturing, LLC is a leading provider of product commercialization services for low-medium volume, high-complexity products to international blue-chip aerospace and defense, industrial, and medical companies. With manufacturing facilities in Springfield and Wilmington, MA, Longmont, CO, San Marcos, Fremont and San Jose, CA, Suzhou, China and Tijuana, Mexico, OnCore manages customers’ high-complexity products while providing them maximum flexibility to manage their business in a close, collaborative relationship.

Trion Technology

Trion Technology is a Clearwater, FL-based company in the Computers and Electronics sector.

Atmosic

Atmosicâ„¢ Technologies is an innovative fabless semiconductor company, designing ultra-low power wireless solutions to dramatically reduce and disrupt device dependency on batteries, aiming to deliver forever battery life and the battery free connected Internet of Things.

Xceleron

Xceleron believes that AMS technology and our expertise can get life-changing products (drugs and biobased) quickly and cost-effectively to people who need them.  We work with integrity and an open mind and are driven by science and the spirit of collaboration. Founded in 1997 in York, UK, and now headquartered in Germantown, Maryland, Xceleron pioneered human microdose and microtracer techniques using AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I, and Phase II/III clinical trials. Xceleron’s experience is especially valuable because the characteristics of many contemporary small molecules (low solubility, long half-life and disproportionate human metabolites) mean that their early pharmacokinetic and metabolic characterization is critical to the cost-effectiveness of clinical development.